AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06538831 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet N+P+
Description: Rich in SFAs, free sugar and sodium; High in UPFs
Study NCT05598203 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Operative group of nutrition education
Description: The intervention will be carried out with operational nutritional education groups. Four meetings will be held, each meeting lasting one hour, weekly or fortnightly (according to the availability of the patient). The following foods proposed foods: Meeting 1 = education on classification labels and proposed foods proposed foods (education on classification labels and substitution of Brazilian foods), in this guide meeting the proposal is processed or ultra-processed by an in natura food or minimally processed; Meeting 2 = assembly of the healthy dish (food portions, food index and glycemic load, food clothes), the proposal in this meeting is the assembly of the complete dish in the meals eaten throughout the day; and Encounter 3 = hunger and satiety (aiming to increase the perception of hunger and satiety signals), encounter as a task to be accomplished; Encounter 4 = strengthening change, barriers and difficulties in maintaining habits based on the transtheoretical model of change.
Study NCT05598203 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Operative group of nutrition education
Description: The intervention will be carried out with operational nutritional education groups. Four meetings will be held, each meeting lasting one hour, weekly or fortnightly (according to the availability of the patient). The following foods proposed foods: Meeting 1 = education on classification labels and proposed foods proposed foods (education on classification labels and substitution of Brazilian foods), in this guide meeting the proposal is processed or ultra-processed by an in natura food or minimally processed; Meeting 2 = assembly of the healthy dish (food portions, food index and glycemic load, food clothes), the proposal in this meeting is the assembly of the complete dish in the meals eaten throughout the day; and Encounter 3 = hunger and satiety (aiming to increase the perception of hunger and satiety signals), encounter as a task to be accomplished; Encounter 4 = strengthening change, barriers and difficulties in maintaining habits based on the transtheoretical model of change.
Study NCT05291585 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the dedicated venous sinus thrombectomy stent
Description: the dedicated venous sinus thrombectomy stent in conjunction with aspiration for CVST patients within 28 days of symptom onset.
Study NCT06664138 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Remimazolam
Description: Remimazolam is a recently approved medication used for the induction of general anesthesia and maintenance of sedation. There have been no prior studies using remimazolam for the induction of anesthesia in ECT, and this research aims to investigate the feasibility of using remimazolam as an induction agent for ECT.
Study NCT06664138 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Etomidate
Description: Etomidate is widely used in ECT due to its rapid onset, stable hemodynamic profile, and quick recovery. In this study, remimazolam will be used as the experimental group, while etomidate will serve as the control group.
Study NCT06680687 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Program (video, information booklet, Survivorship Card)
Description: Caregivers will be invited to attend an educational group session. Each session will be organized weekly to monthly. A maximum of ten caregivers can be present at a session.~First a video will be displayed in which healthcare providers explain medical aspects of survivorship. Caregivers of survivors and young adult survivors discuss experiences after completing cancer treatment in the video.~Secondly, the present healthcare provider will hand over an information booklet 'Life after childhood cancer' to the caregivers. The booklet covers similar topics as presented in the video.~Lastly, a Survivorship Card will be shared with the caregivers. The card contains a record of the patient's cancer and treatment history and the expected follow-up appointment schedule. The survivor and family take one card home and a duplicate copy of the card remains in the medical file.
Study NCT06680687 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Follow-Up Program (form and healthcare provider training)
Description: Healthcare providers will attend a training session of approximately 90 minutes, in which investigators will discuss the same topics as covered in the educational group session supported by PowerPoint slides.~A Follow-Up Form will be introduced to be used by healthcare providers in the outpatient follow-up clinic. The form will include questions referring to symptoms specific for certain late effects. Specific questions will be included per subcategory: hematological malignancies, solid tumors or central nervous system (CNS) tumors.
Study NCT06412757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silexan
Description: Participants in the Silexan arm will take two over-encapsulated capsules, each containing 80 mg Silexan, daily orally in the morning in addition to their usual medications. No modifications of allocated interventions will be made for any trial participants; if appropriate (i.e following the emergence of adverse events) participants will be withdrawn from the intervention.
Study NCT06412757 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants in the placebo arm will take two capsules containing an inert placebo daily orally in the morning in addition to their usual medications. The placebo capsules will contain a sub-therapeutic amount of lavender oil to mimic the odor of the experimental drug (Silexan).
Study NCT06675526 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Detour
Description: Detour is a mobile game designed to assist youth with smoking cessation. First, Detour targets stimuli devaluation using a gamified go/no-go training. Second, the researchers aimed to reduce delay discounting in two ways; 1) players can replace neutral images in the go/no-go training with positive images from their own lives related to their future self; 2) players can set and monitor personal goals via the game, to promote future-self priming. Third, participants join a social shell comprising Instagram and TikTok content to provide psychoeducation about quitting smoking and to interact with fellow players who quit simultaneously. Finally, the timing and content of in-game messaging is personalized to each participant based on information provided in an ecological momentary assessment component and a stop plan filled out during the week before the quit attempt.
Study NCT06675526 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-help brochure
Description: The brochure provides guidelines to independently design a stop-plan including questions about seeking support from others, strategies to fight cravings, and setting rewards for milestones after quitting. Participants will be encouraged to complete this stop-plan in week 0 of the intervention, so the week before quit day. Additionally, the brochure includes psychoeducational information that is valuable when planning to quit smoking.
Study NCT06684886 — intervention group
Intervention type: OTHER
Intervention: Ankle Brachial Index
Description: Normal ABI ranges from 1.0 - 1.4~* Pressure is normally higher in the ankle than the arm.~* Values above 1.4 suggest a noncompressible calcified vessel.~* In diabetic or elderly patients, the limb vessels may be fibrotic or calcified. In this case, the vessel may be resistant to collapse by the blood pressure cuff, and a signal may be heard at high cuff pressures. The persistence of a signal at a high pressure in these individuals results in an artifactually elevated blood pressure value.~* An value below 0.9 is considered diagnostic of PAD.~* Values less than 0.5 suggests severe PAD.~* Individuals with such severe disease may not have sufficient blood flow to heal a fracture or surgical wound; they should be considered for revascularization if they have a non-healing ulcer.
Study NCT06682741 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: supervised exercise training; twice a week for 12 months
Study NCT06682884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorlatinib 100 mg
Description: Eligible patients will be registered to receive oral lorlatinib 100mg qd for 6-8 weeks each during the neoadjuvant therapy phase
Study NCT06683313 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: combination femoral nerve and popliteal sciatica block
Description: Combination of femoral nerve and popliteal sciatica block performed after knee surgery
Study NCT06683313 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: combination adductor canal and IPACK block
Description: Combination of adductor canal and IPACK block performed after knee surgery
Study NCT05291585 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balloon catheter thrombectomy
Description: Intracranial thrombectomy was conducted by using a balloon catheter in conjunction with aspiration as control group.
Study NCT05097599 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: lorlatinib
Description: This arm of the Strata PATH trial will assess the clinical benefit of Lorbrena® (lorlatinib) in ALK and ROS1 gene fusion positive solid tumors, as detected by Strata testing, with the exception of NSCLC.
Study NCT05097599 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: encorafenib + binimetinib
Description: This arm of the Strata PATH trial will assess the clinical benefit of Braftovi® (encorafenib) + Mektovi® (binimetinib) in BRAF p.v600X mutated solid tumors, as detected by Strata testing, with the exception of melanoma and colorectal cancer.
Study NCT05097599 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: talazoparib
Description: This arm of the Strata PATH trial will assess the clinical benefit of Talzenna® (talazoparib) in patients with advanced solid tumors harboring deep deletions or deleterious mutations with LOH in BRCA1/2 and PALB2, as detected by Strata testing, excluding HER2 negative breast cancer.
Study NCT05097599 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: sacituzumab govitecan
Description: This arm of the Strata PATH trial will assess the clinical benefit of Trodelvy® (sacituzumab govitecan) in patients with advanced solid tumors and are Trop2 Treatment Response Score High (Trop2 TRS-H), as detected by Strata testing, excluding triple negative breast cancer, hormone receptor positive/ human epidermal growth factor receptor 2 negative (HR+/HER2-) breast cancer, metastatic urothelial cancer, non-small cell lung (NSCLC) cancer, small cell lung cancer (SCLC), head and neck cancer, colorectal cancer (CRC), and endometrial cancer.
Study NCT05097599 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: axitinib
Description: This arm of the Strata PATH trial will assess the clinical benefit of Inlyta® (axitinib) in patients with advanced solid tumors and are Angiogensis Inhibitor Treatment Response Score High (Angio TRS-H), as detected by Strata testing, excluding renal cell carcinoma, alveolar soft part sarcoma, and solitary fibrous tumors.
Study NCT05097599 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fam-Trastuzumab Deruxtecan-Nxki
Description: This arm of the Strata PATH trial will assess the clinical benefit of Enhertu ® in patients with advanced solid tumors with Her2 overexpression
Study NCT05097599 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: enfortumab vedotin
Description: This arm of the Strata PATH trial will assess the clinical benefit of Padcev® in patients with advanced solid tumors with nectin-4 overexpression
Study NCT04709172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefditoren pivoxil 400mg
Description: Cefditoren pivoxil 400mg bid for 7 days
Study NCT04980664 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated intervention strategies
Description: Implementation of integrated intervention strategies to reduce the proportion of indicated-but-not-treated CHB patients.
Study NCT05878990 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Culturally-tailored Tobacco Treatment
Description: Weekly telephone calls with a certified tobacco treatment specialist (CTTS) for 6 weeks. The culturally-tailored tobacco intervention content by week via telephone call with the CTTS includes among others: Reasons and Motivations for Quitting, Benefits of Quitting, Stress Management and Discussion about Environmental Influences.
Study NCT04642456 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: EOS stereoradiographic full body exam
Description: Every subject included in the study will undergo a stereoradiographic full body EOS exam completed with Gravity Line (GL) location, recorded by a force plate on the floor
Study NCT04642456 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Balance Assessment Scale 2
Description: Repeating the newly developed balance test (test-retest reliability) within 2 weeks after first measurement
Study NCT04642456 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Trunk strength measurement with EMG 2
Description: Repeating the trunk strength protocol with EMG within 2 weeks after the first measurement (test-retest reliability)
Study NCT04954131 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Candidate Vaccine, SCB-2019
Description: 30 μg of SCB-2019 antigen, and 1.5 mg CpG 1018 and 0.75 mg Alhydrogel as adjuvants
Study NCT04954131 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution (0.9%)
Study NCT06383559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib and Sintilimab
Description: XELOX regimen combined with Sintilimab and Lenvatinib
Study NCT06375590 — intervention group
Intervention type: DEVICE
Intervention: Transcatheter Aortic Valve Implantation
Description: Transcatheter treatment of bicuspid stenosis with the Navitor platform
Study NCT05474625 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High Intensity Laser Therapy
Description: For each 25 cm² of painful area, 1.02 minutes of treatment will give in the analgesic phase, with an energy of 8.0 watt, a dose of 5 Joules/ cm², a frequency of 25 Hertz(Hz) and a total energy of 125 joules. The application time for one session was approximately 15 minutes. Total 15 sessions will be applied to the neck area for a period of 3 weeks, 5 days a week.
Study NCT05474625 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: This treatment was applied to the cervical paravertebral region with a direct contact with the skin with the aid of an ultrasonic gel, at a dose of 1 megahertz(MHz) and 1.5 Watt/cm² for 4 minutes
Study NCT05474625 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous nerve stimulation (TENS)
Description: TENS was performed using 4 adhesive electrodes 5 × 5 cm size in the cervical paravertebral region, 80 Hertz (Hz) frequency and 180 miliseconds current for 20 minutes.
Study NCT05474625 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: A specific program consisted of 15 minutes exercise sessions was provided under the supervision of a physiotherapist . All patients will perform isometric strengthening exercises, active range of motion exercises, and cervical region stretching exercises for 15 sessions (during 3 weeks, on weekdays).
Study NCT05647421 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IOL implantation
Description: after phacoemulsification of the cataract , implantation of Acrysof IQVIVITY IOL .
Study NCT05647421 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IOL implantation
Description: after phacoemulsification of the cataract , implantation of TECNIS Synergy™ Intraocular Lens (Model ZFR00V )
Study NCT05107440 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BREATHE
Description: A virtual, multidisciplinary, patient-centred self-management program for long COVID. The BREATHE program provides education on Breathing, Rest/recovery, Education, Activity management, Thinking/cognition, Healthy voice strategies, and Eating/nutrition.
Study NCT04753736 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intrauterine administration of hCG-activated peripheral blood mononuclear cells
Description: Intrauterine administration of hCG-activated peripheral blood mononuclear cells
Study NCT06118723 — intervention group
Intervention type: PROCEDURE
Intervention: Supramaximal resection
Description: Supramaximal resection. Tumor resection continues until either the FLAIR abnormalities have been resected based on the neuronavigation (after updating the navigation intraoperatively), or when subcortical tracts are identified with intraoperative stimulation.
Study NCT06118723 — intervention group
Intervention type: PROCEDURE
Intervention: Maximal safe resection
Description: Maximal safe resection. Tumor resection continues until maximal safe resection has been achieved as by the neurosurgeon's opinion.
Study NCT06225856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YY201
Description: Oral administration under fasting state.
Study NCT05210829 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: stationary and trait anxiety scale
Description: survey
Study NCT04441281 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Traction of the cervix for IUD insertion
Description: Limited mobility of the uterine cervix and alignment with the vaginal canal is often required during insertion of an intrauterine contraceptive device (IUD).
Study NCT04441281 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traction of the cervix for IUD insertion
Description: Limited mobility of the uterine cervix and alignment with the vaginal canal is often required during insertion of an intrauterine contraceptive device (IUD).
Study NCT05982665 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Molecular hydrogen
Description: Hydrogen gas, purity >99.9%, flow rate 300 ml/min.
Study NCT05982665 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ambient air, flow rate 300 ml/min.
Study NCT04782934 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The YANG SENSOR is an active implantable device, for Real Time Continuous Glucose, Lactate and Ketone Measurement
Description: The YANG SENSOR is an active implantable device, that is intended to be implanted in the subcutaneous abdominal tissue, approximately 10mm below the skin. The SENSOR is battery powered. The battery is wirelessly recharged through the skin by the YANGEXD, using a charging coil ('Donut') applied to the skin with an adhesive patch at the level of the SENSOR. The 'Donut' also receives data from the sensor.
Study NCT05878990 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Culturally-tailored Content Newsletters
Description: Weekly newsletters covering topics such as Race and Smoking, Nicotine Replacement Therapy (NRT) Reasons and Motivations for Quitting, Benefits of Quitting and other related topics.
Study NCT05878990 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Preference Scale
Description: Survey to elicit preference on the decision-making interaction with healthcare provider. The survey uses a 5 point scale from 1 to 5 with 1 or 2 points representing Active Control Preference; 3 or 4 representing a Collaborative Control Preference and 5 representing a Passive Control Preference.
Study NCT05417048 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Sample
Description: Up to 5mL of blood via venipuncture
Study NCT04535609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mavodelpar
Description: Once daily
Study NCT04535609 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily
Study NCT06126809 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Steep-tRAS
Description: Stimulation will be delivered via the NeuroConn Direct Current Stimulator Plus Multiple Channels, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research.
Study NCT06126809 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flat-tRAS
Description: Stimulation will be delivered via the NeuroConn Direct Current Stimulator Plus Multiple Channels, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research.
Study NCT06126809 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-tRAS
Description: Stimulation will be delivered via the NeuroConn Direct Current Stimulator Plus Multiple Channels, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research.
Study NCT05878990 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Content Newsletter or Passive Content Newsletter
Description: Based on the answers to the Control Preference Scale, participants will receive the appropriate weekly newsletter (active content or passive content). Newsletters are covering topics such as Race and Smoking, Nicotine Replacement Therapy (NRT) Reasons and Motivations for Quitting, Benefits of Quitting and other related topics presented in a more passive or active manner.
Study NCT04936854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus 1 mg Oral Tablet
Description: 2 mg Sirolimus (two 1 mg tablets) on the first day, followed by 0,5 mg Sirolimus (half 1 mg tablet) per day for 12 weeks.
Study NCT04936854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: 500 mg Methylprednisolone intravenously once a week for 6 weeks, followed by 250 mg once a week for 6 weeks. Total period of treatment 12 weeks.